Discovery of a Conditionally Activated IL-2 that Promotes Antitumor Immunity and Induces Tumor Regression

IL-2 is a cytokine clinically approved for the treatment of melanoma and renal cell carcinoma. Unfortunately, its clinical utility is hindered by serious side effects driven by the systemic activity of the cytokine. Here, we describe the design and characterization of a conditionally activated IL-2...

Descripción completa

Detalles Bibliográficos
Autores principales: Nirschl, Christopher J., Brodkin, Heather R., Hicklin, Daniel J., Ismail, Nesreen, Morris, Kristin, Seidel-Dugan, Cynthia, Steiner, Philipp, Steuert, Zoe, Sullivan, Jenna M., Tyagi, Ethika, Winston, William M., Salmeron, Andres
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381102/
https://www.ncbi.nlm.nih.gov/pubmed/35286392
http://dx.doi.org/10.1158/2326-6066.CIR-21-0831

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381102/
https://www.ncbi.nlm.nih.gov/pubmed/35286392
http://dx.doi.org/10.1158/2326-6066.CIR-21-0831

Ejemplares similares